CO129 Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy (RWPC) for Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)
Year: 2023
Type: conference-abstract
Source: Value in Health
Authors: A. Krishnan, A. Nooka, A. Chari, A.L. Garfall, T. Martin, S. Nair, X. Lin, K. Qi, A. Londhe, L. Pei, E. Ammann, K. Chastain, T. Parekh, A. Marshall, M. Slavcev, S.Z. Usmani
Institutions: City of Hope, Emory University, Winship Cancer Institute, Icahn School of Medicine at Mount Sinai, Abramson Cancer Center, University of Pennsylvania, University of California, San Francisco, Janssen (Belgium), Janssen Research & Development (United States), Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4390126551